SCHEDULE 13D

CUSIP Number(s):

G8128Y157

Name of reporting person

Richard Griffiths

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

JERSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 30,844,458.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 30,844,458.00
10	Shared Dispositive Power 0.00

Aggregate amount beneficially owned by each reporting person

30,844,458.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

21.7 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person:

* Consists of (i) 19,155,522 ordinary shares represented by American Depositary Shares ("ADSs") held by Ora Capital Limited; (ii) 1,815,522 ordinary shares represented by ADSs held by Sarossa Plc; (iii) 3,000,000 ordinary shares represented by ADSs held by Cream Capital Limited; ; (iv) 300,000 ordinary shares represented by ADSs held by Blake Holdings Limited; (v) 360,000 ordinary shares represented by ADSs held by Ora Ventures Limited; (vi) 190,500 ordinary shares represented by ADSs held by Pinkey's Limited; and (vii) 6,022,914 ordinary shares represented by ADSs held by Mr. Griffiths. Each ADS represents, and at the holder's option is convertible into, three ordinary shares of the Issuer. Mr. Griffiths is a director and the controlling shareholder of each of Ora Capital Limited, Ora Ventures Limited, Blake Holdings Limited, Sarossa Plc and Cream Capital Limited and a controlling shareholder of Pinkey's Limited and possesses the power to direct the voting and disposition of these shares. **This percentage is calculated based upon the 141,701,847 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing.

SCHEDULE 13D

CUSIP Number(s):

G8128Y157

Name of reporting person

Ora Capital Limited

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

JERSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 19,155,522.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 19,155,522.00
10	Shared Dispositive Power 0.00

Aggregate amount beneficially owned by each reporting person

19,155,522.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

13.5 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person:

* Consists of 19,155,522 ordinary shares represented by ADSs held by Ora Capital Limited. **This percentage is calculated based upon the 141,701,847 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing.

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Ordinary Shares, nominal value of PS0.05 per share

(b)

Name of Issuer:

Silence Therapeutics Plc

(c)

Address of Issuer's Principal Executive Offices:

72 Hammersmith Road, London, UNITED KINGDOM , W14 8TH.

Item 1 Comment:

This Amendment No. 10 to Schedule 13D (this "Amendment"), which amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on June 15, 2022, as amended on July 20, 2022, October 20, 2022, August 14, 2023, March 27, 2024, December 18, 2024, March 31, 2025, April 24, 2025, May 8, 2025 and June 25, 2025 (the "Schedule 13D") on behalf of Richard Ian Griffiths, relates to the ordinary shares, nominal value PS0.05 per share (the "Shares"), of Silence Therapeutics plc (the "Issuer"). This Amendment is being filed to reflect the open market transactions of the Issuer's ADSs by the Reporting Person together with dilution as a result of an increase in the share capital of the Issuer. Except as amended and supplemented hereby, the Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Schedule 13D.

Item 2.

Identity and Background

(a)

Richard Griffiths

(b)

19-21 Broad Street, St Helier, Jersey, JE2 3RR

(d)

n/a

(e)

n/a

(f)

Jersey, Channel Islands

Item 3.

Source and Amount of Funds or Other Consideration

Mr. Griffiths sold an aggregate of 1,544,374 ADSs in open market transactions between June 29, 2026 and July 6, 2026 for aggregate sales proceeds of $16.3M.

Item 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

n/a

Item 7.

Material to be Filed as Exhibits.

A. Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. B. Schedule 1 Transactions in ADSs During the Past Sixty Days

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Richard Griffiths

Signature:	/s/ Richard Ian Griffiths
Name/Title:	Richard Ian Griffiths
Date:	07/07/2026

Ora Capital Limited

Signature:	/s/ Richard Ian Griffiths
Name/Title:	Director
Date:	07/07/2026